Articles Tagged With:
-
NIH issues guidance promoting central IRB use
The National Institutes of Health (NIH) is officially promoting the use of a single IRB for large, multisite clinical trials.
-
SUPPORT study that started controversy was complicated
A study called SUPPORT, short for Surfactant, Positive Pressure, and Oxygenation Randomized Trial, was a major reason behind recent draft guidance published by the Office for Human Research Protections (OHRP).
-
Standard of Care Draft Guidance Praised, Criticized
Weighing in on a recent standard of care guidance published by the Office for Human Research Protections.
-
Internal Medicine [ALERT]
The United States Preventive Services Task Force (USPSTF) gave a level B recommendation in support of annual low-dose computed tomography (LDCT) to screen for lung cancer in appropriate risk groups. The USPSTF decision was largely based on the National Lung Screening Trial (NLST), a mega-trial (n = 53,454) in the United States that randomized subjects to annual LDCT or chest X-ray. The primary endpoint of the study was lung cancer mortality, and all-cause mortality was a secondary endpoint. Inclusion criteria included at least a 30-pack/year history of smoking (if stopped within 15 years), ability and willingness to complete follow-up for abnormal findings, and absence of problematic comorbidities that might otherwise compromise long-term survival.
-
Human Papillomavirus 9-valent Vaccine, Recombinant (Gardasil® 9)
The FDA has approved a 9-valent human papillomavirus (HPV) vaccine. The new vaccine covers five more types of HPV than the previous vaccine and protects against 90% of the HPV strains that cause cervical cancer.1 The new vaccine is marketed by Merck as Gardasil®9.
-
Liraglutide Preserves Beta Cell Function — Well, Kind of…
SYNOPSIS: Fifty-one patients with type 2 diabetes of 2.6 +/- 1.9 years duration and an A1C of 6.8 % completed 4 weeks of intensive insulin therapy in order to eliminate glucose toxicity which is injurious to pancreatic beta cells. Thereafter, patients were randomized to receive daily subcutaneous liraglutide or an equivalent volume of placebo. Serial assessments of beta-cell function following oral glucose tolerance testing was performed at 12 week intervals for 48 weeks. Patients using liraglutide noted a rebust enhancement of beta cell function which was sustained over the course of the trial, yet lost within two weeks after stopping treatment.
-
Medicaid Bump: What Happens After Expiration?
The boost expired Dec. 31 and only a few states have the funds to continue.
-
Heart Failure Patients Bounce Back to ED
Searching for a tool to determine what is interfering with these patients’ ability to care for themselves.
-
Hospitals Designated for Ebola Treatment or Assessment
Public health officials are initiating a program for facilities to assess patients with suspected Ebola before transferring them once the diagnosis is confirmed.
-
Clinical Briefs
The Heavy Emotional Costs of Rosacea, Treatment Choices Among the PDE5 Inhibitors, and Screening Asymptomatic Diabetics with CT angiography